Welcome to our dedicated page for IDEXX LABORATORIES /DE SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEXX LABORATORIES /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEXX LABORATORIES /DE's regulatory disclosures and financial reporting.
Joseph L. Hooley, a director of IDEXX Laboratories, Inc. (IDXX), reported equity awards received in connection with his board service. On 09/01/2025 he was granted 158 restricted stock units (each convertible to one share) and a non-qualified stock option to purchase 364 common shares at an exercise price of $647.09 per share. Both awards vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever is earlier.
These awards represent pro rata non-employee director compensation for service from his election to the board on July 10, 2025 through the 2026 annual meeting. Following the reported transactions, the reporting person beneficially owns 158 shares via RSUs and holds options on 364 shares.
M. Anne Szostak, a director of IDEXX Laboratories, reported multiple transactions on 08/22/2025. She exercised a non-qualified stock option to acquire 2,187 shares at an exercise price of $206.62 per share and, on the same date, sold 2,187 shares at a weighted average price of $647.3252 per share. She also reported two gift transactions of 259 shares each: one reducing her direct holdings and one reflecting shares held by related trusts/foundations. Following the reported transactions, the filing shows 262 shares held directly and identified indirect interests via a trust and a family foundation.
Idexx Laboratories (IDXX) Form 144 notice: An insider intends to sell 2,187 shares of common stock, representing an aggregate market value of $1,415,700.21, on 08/22/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired the same day via stock option exercise and paid in cash. There were 80,004,694 shares outstanding reported for the issuer. The filer reports no sales in the prior three months. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Idexx Laboratories (IDXX) reporting person Michael G. Erickson sold a total of 405.892 shares on 08/12/2025 in two non-derivative transactions, at prices around $649.85 to $650.00 per share. The filing shows two S-code sales: 318 shares at $649.99 and 87.892 shares at a weighted-average price of $649.8507. Following these transactions Erickson is reported to beneficially own 11,286.97 shares (the filing also lists 11,374.862 shares following the larger sale), and the filing notes 26.4960 shares previously purchased under the Issuer Employee Stock Purchase Plan.
The Form 4 was signed by an attorney-in-fact on 08/14/2025 and includes an undertaking to provide details on the number of shares sold at each price upon request. All information here is stated explicitly in the filing.
Amendment to Form 5 for Michael G. Erickson, Executive Vice President of IDEXX Laboratories (IDXX). The amended filing corrects a previously reported omitted holding: on January 21, 2025 a Form 5 mistakenly reported an omitted holding of 8,588 shares. As of the issuer's fiscal year end 12/31/2024 the reporting person beneficially owned 9,742.366 shares. The filing states the overstatement was propagated into subsequent Forms 4 filed after the original Form 5 and before this amendment. The amendment is signed by an attorney-in-fact on behalf of the reporting person and dated 08/14/2025. The document contains no additional financial results, transactions with prices, or commentary beyond the ownership correction.
Michael G. Erickson amended his initial Form 3 reporting ownership in IDEXX LABORATORIES INC (IDXX). The filing shows 9,377.366 shares of common stock held directly by the reporting person. The amendment corrects an earlier overstatement: the original Form 3 overstated beneficial ownership by 961.9957 shares, an error the filer says was also carried into subsequent Forms 4 and 5 and is now corrected. The event date requiring the statement is 01/01/2024 and the amendment references an original filing dated 01/05/2024. The form identifies the reporting person as an Officer (Executive Vice President) and was signed by an attorney-in-fact on 08/14/2025.
Nimrata Hunt, Executive Vice President of IDEXX Laboratories, reported transactions in the issuer's common stock (ticker IDXX). The filing shows a sale and subsequent option exercises that largely offset each other. On 08/11/2025 she sold 1,200 shares at $656.5335, leaving 16,806.9435 shares held directly. On 08/12/2025 she acquired shares through the exercise of previously granted options: 560 at $178.26, 483 at $206.94, and 183 at $544.08, bringing direct beneficial ownership to 18,032.9435 shares. The filing also notes 160 shares held indirectly, jointly with a spouse. The exercised options correspond to grants that became exercisable in one installment on Feb 14, 2023, Feb 14, 2024, and Feb 14, 2025.
Form 144 notice for IDEXX Laboratories (IDXX) reports a proposed sale of 407 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $264,533.53. The filing lists the company's outstanding shares as 80,004,694, so the proposed sale represents approximately 0.00051% of outstanding stock. The acquisition history provided shows the shares originated from multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, with acquisition dates ranging from 06/30/2021 through 03/29/2024. The filer certifies they are not aware of undisclosed material adverse information and uses Morgan Stanley as the executing broker. The proposed approximate sale date is 08/12/2025.
Sharon E. Underberg, EVP, General Counsel & Corporate Secretary of IDEXX Laboratories (IDXX), filed a Form 4 reporting stock and option activity on 08/08/2025 and 08/12/2025. The filing shows non-derivative and derivative transactions including an acquisition of 5,450 common shares (08/08/2025) and a same-day disposition of 5,450 common shares (08/08/2025), and an acquisition of 183 common shares (08/12/2025). The record lists beneficial ownership following the reported transactions at 6,338.6539 shares.
The Form 4 also reports derivative holdings: a non-qualified stock option covering 5,450 underlying shares (exercise price shown as $206.94) and an incentive stock option covering 183 underlying shares (exercise price shown as $544.08). The filing includes an explanatory note that 28.7090 shares were purchased under the Issuer Employee Stock Purchase Plan during March and June 2025. The form is signed by an attorney-in-fact on behalf of Ms. Underberg on 08/12/2025.
Jonathan Jay Mazelsky, who is reported as a Director and the President and CEO of IDEXX Laboratories, reported an insider transaction involving common stock and a related option. The Form 4 shows an acquisition of 183 shares of common stock on 08/08/2025 at a price of $598.488 per share, with reported beneficial ownership following the transaction of 83,494.3016 shares (direct).
The filing also discloses a Premium Incentive Stock Option tied to 183 underlying shares with an exercise/conversion price of $598.488. The explanatory note states the option was granted at a 110% premium to the closing price on February 12, 2021 and became exercisable in one installment on February 14, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Mazelsky.